Limits...
Expression of the Cancer Stem Cell Markers CD44 and CD133 in Colorectal Cancer: An Immunohistochemical Staining Analysis.

Hong I, Hong SW, Chang YG, Lee WY, Lee B, Kang YK, Kim YS, Paik IW, Lee H - Ann Coloproctol (2015)

Bottom Line: No significant correlation was found between the CD44 and the CD133 expressions.Multivariate analysis proved that low expression of CD44 was an independent prognosis factor for short disease-free survival (P = 0.028).Low CD44 expression was correlated with increased tumor recurrence and short disease-free survival, and low CD133 expression was associated with advanced tumor stage.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Inje University Seoul Paik Hospital, Seoul, Korea.

ABSTRACT

Purpose: The aim of this study was to assess the expressions of CD44 and CD133 in colorectal cancer tissue by using immunohistochemical staining and to analyze the clinical significance of the expressions related to other clinicopathological data and survival results.

Methods: One hundred sixty-two patients with a biopsy-proven colorectal adenocarcinoma who were operated on between January 1998 and August 2004 were enrolled in this study. Immunohistochemical staining for CD44 and CD133 was performed on primary colorectal cancer tissue, metastatic lymph nodes, and synchronous and metachronous metastatic tumor tissues if available.

Results: CD44 expression was stronger in the primary tumor than in metastatic lymph nodes (P < 0.001), and CD133 expression tended to be stronger in primary tumor than in metastatic lymph nodes (P = 0.057). No significant correlation was found between the CD44 and the CD133 expressions. The cases with recurrence showed low expression of CD44 (P = 0.017). CD133 expression was lower in cases with elevated CA 19-9 serum levels (P = 0.028) and advanced T stage (P = 0.038). Multivariate analysis proved that low expression of CD44 was an independent prognosis factor for short disease-free survival (P = 0.028).

Conclusion: Low CD44 expression was correlated with increased tumor recurrence and short disease-free survival, and low CD133 expression was associated with advanced tumor stage. We suggest that further studies be performed to evaluate whether the immunohistochemical method for determining the CD44 and the CD133 expressions is appropriate for exploring cancer stem-cell biology in patients with colorectal cancer.

No MeSH data available.


Related in: MedlinePlus

Relationship between CD44 and CD133 expressions in a colorectal adenocarcinoma.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4496458&req=5

Figure 2: Relationship between CD44 and CD133 expressions in a colorectal adenocarcinoma.

Mentions: No significant correlation was noted between CD44 expression and CD133 expression in the primary tumor (P = 0.466) (Fig. 2). The relationships between CD44 and CD133 expressions in the primary tumor and the other clinicopathological characteristics were analyzed. The patients in which recurrence developed during the follow-up period showed low expression rates of CD44 (P = 0.017). In rectal cancer, the CD133 expression rate was higher than that it was in colon cancer (P = 0.017). The CD133 expression rate was lower in cases with elevated CA 19-9 serum levels (P = 0.028) and advanced T stage (P = 0.038) (Table 3). No significant correlation were noted between other clinicopathological factors, including gender, age, tumor size, gross appearance of tumor, CEA, TNM stage, and histology (differentiation of tumor), and the CD44 and the CD133 expressions in the primary tumor.


Expression of the Cancer Stem Cell Markers CD44 and CD133 in Colorectal Cancer: An Immunohistochemical Staining Analysis.

Hong I, Hong SW, Chang YG, Lee WY, Lee B, Kang YK, Kim YS, Paik IW, Lee H - Ann Coloproctol (2015)

Relationship between CD44 and CD133 expressions in a colorectal adenocarcinoma.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4496458&req=5

Figure 2: Relationship between CD44 and CD133 expressions in a colorectal adenocarcinoma.
Mentions: No significant correlation was noted between CD44 expression and CD133 expression in the primary tumor (P = 0.466) (Fig. 2). The relationships between CD44 and CD133 expressions in the primary tumor and the other clinicopathological characteristics were analyzed. The patients in which recurrence developed during the follow-up period showed low expression rates of CD44 (P = 0.017). In rectal cancer, the CD133 expression rate was higher than that it was in colon cancer (P = 0.017). The CD133 expression rate was lower in cases with elevated CA 19-9 serum levels (P = 0.028) and advanced T stage (P = 0.038) (Table 3). No significant correlation were noted between other clinicopathological factors, including gender, age, tumor size, gross appearance of tumor, CEA, TNM stage, and histology (differentiation of tumor), and the CD44 and the CD133 expressions in the primary tumor.

Bottom Line: No significant correlation was found between the CD44 and the CD133 expressions.Multivariate analysis proved that low expression of CD44 was an independent prognosis factor for short disease-free survival (P = 0.028).Low CD44 expression was correlated with increased tumor recurrence and short disease-free survival, and low CD133 expression was associated with advanced tumor stage.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Inje University Seoul Paik Hospital, Seoul, Korea.

ABSTRACT

Purpose: The aim of this study was to assess the expressions of CD44 and CD133 in colorectal cancer tissue by using immunohistochemical staining and to analyze the clinical significance of the expressions related to other clinicopathological data and survival results.

Methods: One hundred sixty-two patients with a biopsy-proven colorectal adenocarcinoma who were operated on between January 1998 and August 2004 were enrolled in this study. Immunohistochemical staining for CD44 and CD133 was performed on primary colorectal cancer tissue, metastatic lymph nodes, and synchronous and metachronous metastatic tumor tissues if available.

Results: CD44 expression was stronger in the primary tumor than in metastatic lymph nodes (P < 0.001), and CD133 expression tended to be stronger in primary tumor than in metastatic lymph nodes (P = 0.057). No significant correlation was found between the CD44 and the CD133 expressions. The cases with recurrence showed low expression of CD44 (P = 0.017). CD133 expression was lower in cases with elevated CA 19-9 serum levels (P = 0.028) and advanced T stage (P = 0.038). Multivariate analysis proved that low expression of CD44 was an independent prognosis factor for short disease-free survival (P = 0.028).

Conclusion: Low CD44 expression was correlated with increased tumor recurrence and short disease-free survival, and low CD133 expression was associated with advanced tumor stage. We suggest that further studies be performed to evaluate whether the immunohistochemical method for determining the CD44 and the CD133 expressions is appropriate for exploring cancer stem-cell biology in patients with colorectal cancer.

No MeSH data available.


Related in: MedlinePlus